Vanda Pharma Launches NEREUS for Motion Sickness in US

Key Announcement

Vanda Pharmaceuticals Inc. has announced the commercial launch of NEREUS™ tradipitant across the United States. The medication is approved for the prevention of vomiting induced by motion sickness in adults, marking a significant milestone for the company.

Market Overview

NEREUS™ is the first new prescription medicine approved for this condition in more than 40 years, addressing a market of an estimated 65 to 78 million American adults who experience motion sickness. As a neurokinin-1 receptor antagonist, it works by blocking the vomiting center in the brain. The FDA approval was based on two successful Phase 3 clinical trials conducted in real-world conditions.

Economic and Commercial Impact

Vanda has initiated a direct-to-consumer platform, offering NEREUS™ at a cash-pay price of $85 per dose, compared to the standard list price of $255. This strategy, alongside nationwide retail pharmacy availability, aims to enhance patient access. The news also appeared to cause brief market confusion, as shares of Atossa Genetics Inc. saw a jump in trading activity.

Summary

The U.S. launch of NEREUS™ positions Vanda Pharmaceuticals to capture a substantial, underserved market. The direct-to-consumer pricing model and its status as a novel treatment will be critical factors in its commercial success and impact on VNDA stock performance.

FAQ

Q: What is NEREUS™?
A: It is a new FDA-approved prescription drug from Vanda Pharmaceuticals designed to prevent vomiting from motion sickness in adults.

Q: What is the price of NEREUS™?
A: The standard list price is $255 per dose, but it is available for a cash-pay price of $85 per dose through its official website, nereus.us.

Source: Investing.com